Earnings call transcript: Haemonetics Q3 2024 sees EPS beat, stock drops
Haemonetics Corporation (market cap: $3.23B) reported its third-quarter earnings for fiscal year 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $1.19, slightly ...
McKesson’s Broad-Based Growth Is Fueled by GLP-1s, New Customers, and a Growing Specialty Portfolio
Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...